Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Nuvectis Pharma, Inc.NASDAQ: NVCT
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$105.74M, compared with -$78.58M a year earlier.
Context
- Retained earnings amounted to 416.3% of total assets at the end of Q1 FY2026, up 155.7 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -34.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (99.69M) USD
- Year-over-year change
- -36.1%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (99.69M) | -36.1% |
| FY2024 | 2024-12-31 | (73.25M) | -35.0% |
| FY2023 | 2023-12-31 | (54.25M) | -69.6% |
| FY2022 | 2022-12-31 | (31.99M) | -147.9% |
| FY2021 | 2021-12-31 | (12.9M) | — |
Retained Earnings vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's Mar 2026 retained earnings of -$105.74M is the highest of the 11 companies compared; the peer median is -$950.41M.
- Its year-over-year change of -34.6% is the 8th highest of 11, against a peer median of -18.9%.
- Retained earnings amounts to 416.3% of total assets for NVCT, versus a peer median of 192.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$105.74M | -34.6% | — | 416.3% | |
| Mar 2026 | -$114.55M | -44.0% | — | 119.6% | |
| Mar 2026 | -$375.74M | -43.8% | — | 36.5% | |
| Mar 2026 | -$449.49M | -17.9% | — | 219.1% | |
| Mar 2026 | -$507.54M | -7.5% | — | 1249.7% | |
| Mar 2026 | -$728.01M | -22.8% | — | 166.7% | |
| Jun 2026 | -$1.17B | -14.6% | — | 157.5% | |
| Mar 2026 | -$1.2B | -19.2% | — | 527.5% | |
| Mar 2026 | -$1.28B | -5.8% | — | 588.0% | |
| Mar 2026 | -$1.55B | -18.6% | — | 327.8% | |
| Mar 2026 | -$293.78B | -122645.6% | — | 136.8% | |
| Peer median (excluding NVCT) | -$950.41M | -18.9% | — | 192.9% | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.